Zymeworks加入花旗催化剂手表后上涨

2026-08-11 00:05

Zymeworks (ZYME) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list.
The bank sees shares rising due to an August 25 FDA action date for zanidatamab, sold as Ziihera, as a first-line treatment for gastroesophageal adenocarcinoma. The drug is sold by Jazz Pharmaceuticals (JAZZ).
Ziihera was approved as a second-line treatment under accelerated approval in 2024.
Analyst Yigal Nochomovitz sees approval derisked considering results from the HERIZON-GEA-01 trial.
"Approval would trigger a $250M U.S. milestone and begin unlocking the broader $440M global GEA milestone opportunity, while supporting a larger Ziihera royalty base over time," he added.

More on Zymeworks